Could less chemo mean better quality of life for bladder cancer patients?

NCT ID NCT06892860

Recruiting now Disease control Sponsor: Queen Mary University of London Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares 3 versus 6 cycles of platinum-based chemotherapy followed by the immunotherapy drug avelumab in 320 people with advanced bladder cancer. The goal is to see if fewer chemo cycles improve quality of life without harming cancer control. Participants receive either 3 or 6 cycles of chemo, then avelumab every 2 weeks for up to 2 years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: avelumab (a cancer immunotherapy drug) plus platinum-based chemotherapy (gemcitabine plus cisplatin or carboplatin)
What this could lead to: If successful, this could show that shorter chemotherapy (3 cycles) before immunotherapy is just as effective and improves quality of life for people with advanced bladder cancer.
What could go wrong: This is a phase 2 trial, so results are preliminary. The shorter chemo might not control the cancer as well, and side effects from avelumab (like immune reactions) are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

urinary bladder neoplasm Urinary Bladder Neoplasms urothelial carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

URINARY BLADDER NEOPLASMS

Contacts and locations

Locations

Adknoma
ENROLLING_BY_INVITATION

Madrid, Spain
Barts Health NHS Trust
RECRUITING

London, United Kingdom
Unicancer
RECRUITING

Paris, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.